NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.09 +0.09 (+0.11%) GOLD FUTURES
2,331.60 +20.60 (+0.89%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,227.34 -2,049.28 (-4.24%)
Swedish Orphan Biovitrum AB (publ) (B6E.F)
| Previous close | 24.08 |
| Open | 24.00 |
| Bid | 23.90 x 76000 |
| Ask | 24.18 x 74000 |
| Day's range | 24.00 - 24.36 |
| 52-week range | 16.13 - 26.46 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 8.273B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 45.04 |
| EPS (TTM) | 0.54 |
| Earnings date | 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
PR NewswireSobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
PR NewswireNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
